Literature DB >> 11081200

Proliferation markers in different types of clinically non-secreting pituitary adenomas.

S Schreiber1, W Saeger, D K Lüdecke.   

Abstract

160 clinically non-secreting pituitary adenomas were examined in regard to their expression of the markers PCNA, bcl2, Ki 67 in the mib-1 modification and p53 which are still under investigation for their relevance to cell proliferation. The series contained 60 null cell adenomas, 60 oncocytomas and 40 gonadotroph adenomas. The groups that showed a definitely negative and definitely positive staining were evaluated in regard to their further characteristics such as size, invasiveness and recurrence. PCNA showed a highly represented immunostaining index throughout the groups, but not correlation between the PCNA index and an increased recurrence rate could be found. The staining for bcl2 was only rarely positive and only in a small number of cells. No correlation with the clinical data could be seen. We found a significant higher rate of staining in the invasive adenomas in the group of null cell adenomas and oncocytomas for Ki 67, especially in those adenomas expressing p53. p53 positivity was restricted to the invasive adenomas but was found only in 20% of all invasive adenomas. These data confirm in a sufficiently large series of clinically endocrine inactive pituitary adenomas, that p53 and Ki67 immunohistology is useful in evaluating the aggressive behavior of clinically silent pituitary adenomas. Nevertheless, negative results do not exclude clinically relevant invasive behavior.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081200     DOI: 10.1023/a:1009933820856

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  32 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 2.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

6.  Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc.

Authors:  D G Wang; C F Johnston; A B Atkinson; A P Heaney; M Mirakhur; K D Buchanan
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

7.  Invasiveness of pituitary adenomas.

Authors:  D Sautner; W Saeger
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

8.  Growth rate of human pituitary adenomas.

Authors:  A M Landolt; T Shibata; P Kleihues
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

9.  Image analysis of proliferating cells in tumors of the human nervous system: an immunohistological study with the monoclonal antibody Ki-67.

Authors:  N J Hopf; J Bremm; J Bohl; A Perneczky
Journal:  Neurosurgery       Date:  1994-11       Impact factor: 4.654

Review 10.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

Authors:  A J Levine; M E Perry; A Chang; A Silver; D Dittmer; M Wu; D Welsh
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  24 in total

1.  Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.

Authors: 
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

3.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

4.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

5.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Familial X-Linked Acrogigantism: Postnatal Outcomes and Tumor Pathology in a Prenatally Diagnosed Infant and His Mother.

Authors:  Brittany K Wise-Oringer; George J Zanazzi; Rebecca J Gordon; Sharon L Wardlaw; Christopher William; Kwame Anyane-Yeboa; Wendy K Chung; Brenda Kohn; Jeffrey H Wisoff; Raphael David; Sharon E Oberfield
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

7.  Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas.

Authors:  Erica Hightower; Maria E Cabanillas; Greg N Fuller; Ian E McCutcheon; Kenneth R Hess; Komal Shah; Steven G Waguespack; Lynda J Corley; Jessica K Devin
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

Authors:  A Münscher; M Schmid; W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 9.  [Pituitary gland tumors].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

10.  Heregulin regulates prolactinoma gene expression.

Authors:  George Vlotides; Odelia Cooper; Yen-Hao Chen; Song-Guang Ren; Yona Greenman; Shlomo Melmed
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.